Genentech

edit

Considered the founder of the biotechnology industry, Genentech has been delivering on the promise of biotechnology for more than 30 years, using human genetic information to discover, develop, manufacture and commercialize biotherapeutics that address significant unmet medical needs. Today, Genentech is among the world’s leading biotech companies, with multiple products on the market for serious or life-threatening medical conditions, more than 100 projects in the pipeline and a long term plan for growth.

Milestones

edit

• 
  Genentech invested in 23andMe. (5/1/07)
  Posted 10/15/07 at 9:17am
• 
  Genentech added Arthur D. Levinson as Chairman and CEO.
  Posted 3/21/08 at 9:50am
• 
  Genentech added David Ebersman as CFO.
  Posted 6/29/09 at 11:18am
• 
  Went public with stock symbol DNA.
  Posted 12/10/08 at 11:05am

Videos

Screenshots

edit

Stock Price

Sources

1. 23andme.com [edit]